Have you or someone you know recently suffered a stroke?
If so, you may be eligible to participate in a research study. We are one of over 200 study centers in the United States participating in a clinical trial being conducted in at least 24 countries around the world. In total, approximately 15,500 people will participate.
If you are 55 years or older and have had an ischemic stroke (a blood clot in the brain) within the past 90 days , you may be eligible to participate in this research trial.
Your participation in the study could last 2 – 4 years, depending on when you enter the trial. As part of your study participation you will receive at no cost to you:
• study medication
• study visits
After your initial visits, study participants will be seen approximately every 6 months.
The purpose of this study is to determine which combination of four currently marketed medications is most effective in reducing your risk of having a:
• second stroke or other vascular event such as
• heart attack
• pulmonary embolism
• TIA (“mini-stroke”)
The information gathered from this study may benefit you, and other people just like you.
Spozhmy Panezai, MD at 732-321-7590
or
Albert Obiozo, MD at 732-321-7000 Ext 68897
If you are interested in finding out more about this study, or if you know someone, such as a family member or friend that might be interested in this study, please call the person listed above.
Please note: Profess is Closed for Enrollment.
Sentis: A Single blind study to evaluate the efficacy of Neuroflo device(catheter) in the acute management of ischemic stroke. Patients must be 18yrs and above and should have presented to the ER within 10hrs of stroke onset.
Principal Investigator: Martin Gizzi (MD)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
NTI-ASP-0502: ASP-I (Ancrod in Stroke Program-II): A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute, Ischemic Stroke
Principal Investigator: Martin Gizzi(MD)
Study Coordinator: Albert Obiozo (MD
Assistant Coordinator: Gregory DiBernadino
Novo-cure EF11: An open label study to compare the efficacy of Novo-cure Device versus the best standard of care in the treatment of recurrent Glioblastoma multiforme.
The device involves the use of low intensity, intermediate frequency electric fields to stunt the growth of tumor cells.
Principal Investigator: Joseph Landolfi (DO)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
MRZ 60201-0408: A double blind study to investigate the efficacy and safety of different doses of a muscle relaxant in the treatment of cervical dystonia
Principal Investigator: Philip Hanna(MD
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
Xenoport (XP055): Open Label study to evaluate the safety and efficacy of a medication used to treat Restless Leg Syndrome
Principal Investigator: Arthur Walters(MD)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
SP 793: Open Label study to evaluate the use of a patch medication in treatment of Restless Leg Syndrome
Principal Investigator: Arthur Walters(MD)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
GSK 196: A long-term, open-label continuation study of once daily administration of ropinirole CR tablets to patients with Parkinson's Disease who completed the previous ropinirole CR studies – 167 & 164.
Principal Investigator: Philip Hanna(MD)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
Treatment of insomnia in patients with Parkinson's disease:
A multi-site, placebo-controlled study of eszopiclone
Principal Investigator: Arthur Walters(MD)
Study Coordinator: Albert Obiozo (MD)
Assistant Coordinator: Gregory DiBernadino
For more information on any Clinical Trial listed above, any interested party can call 732-321-7000 x68897.